Thrombotic microangiopathy: Caplacizumab accelerates resolution of acute acquired TTP

Nature Reviews Nephrology 12, 259 (2016). doi:10.1038/nrneph.2016.47 Author: Bernhard Lämmle New data demonstrate that caplacizumab treatment accelerates normalization of platelet count in patients with acute episodes of acquired thrombotic thrombocytopenic purpura (TTP). Although not curative, this drug might reduce ischaemic organ damage and be potentially lifesaving for patients with TTP who do not respond to conventional therapy.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Tags: News and Views Source Type: research